Compare KB Financial Group, Inc. (KB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Tango Therapeutics Inc. — how do they compare? KB Financial Group, Inc. trades at $115.32 (market cap $41.70B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: KB Financial Group, Inc. is far larger — about 11.1× Tango Therapeutics Inc.'s market cap, and KB Financial Group, Inc. pays a 2.83% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Tango Therapeutics Inc. for 0 Days on average.
| KB | TNGX | |
|---|---|---|
Market Cap | $41.70B | $3.74B |
Volume | 251,007 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $132.88 | $32.90 |
52-Week Low | $80.15 | $7.50 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $213.39T | $2.76B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial trades at $121.44, down 0.44% today, with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.79 beating expectations of $3.51. Revenue growth continues from $21.23T in 2025 to projected $22.37T in 2026, while net margins improved to 27.47%. Analyst consensus shows 33% buy ratings with 67% hold, indicating cautious optimism despite technical weakness.
KB presents a value opportunity with attractive valuation metrics including P/E of 9.24 and P/B of 0.9, trading below book value. The main risks include South Korean economic exposure and banking sector volatility, while catalysts include continued earnings momentum and institutional accumulation as seen in Nykredit's recent $10.9M position acquisition.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
